Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR | Market Cap | 3.20M -22.2% |
| Revenue (ttm) | 32.40M +70.0% |
| Net Income | 1.04M |
| EPS | 0.00 |
| Shares Out | 499.41M |
| PE Ratio | 2.13 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,681,620 |
| Open | 0.0066 |
| Previous Close | 0.0064 |
| Day's Range | 0.0062 - 0.0066 |
| 52-Week Range | 0.0030 - 0.6100 |
| Beta | 0.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 29, 2026 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. The company offers HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; pushbutton panels; XPower digital drives for axis and spindle movement; and I/O Line input/output modules. It also provides software solutions include... [Read more]
Financial Performance
Financial StatementsNews
Alterity Aligns With FDA On Phase 3 Design For ATH434 In Treating Multiple System Atrophy
(RTTNews) - Alterity Therapeutics (ATHE), a biotechnology company, on Tuesday reported achieving alignment with the U.S. Food and Drug Administration (FDA) on the planned Phase 3 trial for ATH434 in t...
Cellectis (CLLS) Receives FDA RMAT Designation for CAR-T Therapy, Shares Rise
Cellectis (CLLS) Receives FDA RMAT Designation for CAR-T Therapy, Shares Rise
FDA Accepts Takeda's SBLA For ENTYVIO IV In Pediatric UC And Crohn's Disease; PDUFA Set In Q1,2027
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application or sBLA for intravenous ENTY...
Lilly Receives FDA Nod For EBGLYSS Eight-Week Subcutaneous Maintenance Dose In Atopic Dermatitis
(RTTNews) - Eli Lilly and Company (LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an every-eight-week maintenance dosing schedule for EBGLYSS or lebrikizumab-lbkz (250 mg...
Eli Lilly (LLY) Receives FDA Nod for Ebglyss Maintenance Regimen
Eli Lilly (LLY) Receives FDA Nod for Ebglyss Maintenance Regimen
The FDA just glowed up your sunscreen — by approving a popular ingredient in European and Asian formulas
For decades, US sunscreens lagged behind formulas in Europe and Asia. Now, a new FDA-approved ingredient is helping America catch up.
Takeda (TAK) Gains FDA Review for Pediatric Ulcerative Colitis Treatment
Takeda (TAK) Gains FDA Review for Pediatric Ulcerative Colitis Treatment
FDA cracks down on illegal drug trade, stock worth about ₹25 lakh seized from Pune and Kolhapur
FDA seized illegal medicines worth ₹24.81 lakh in Pune and Kolhapur, including unlicensed antibiotic stocks and improperly promoted Schedule H drugs, officials said.
Birthday cake turns into nightmare as toddler swallows hidden metal pins
Toddler in Thane swallows metal pins hidden in cake decorations; X-ray confirms pins in intestine, passed naturally. Family seeks action under FDA, consumer law.
Medline Industries Faces Regulatory Crisis Amid FDA Warnings (MDLN)
Medline Industries Faces Regulatory Crisis Amid FDA Warnings (MDLN)
FDA approves first new sunscreen ingredient in more than 25 years
Federal health regulators have signed off on the first new sunscreen ingredient for the U.S. market in more than 25 years.
FDA Approves the First New Sunscreen Ingredient in 20 Years
Bemotrizinol is a powerful, broad-spectrum blocker of dangerous rays that has been used in Europe for years.
FDA allows popular sunscreen ingredient long used in Europe and Asia
The Food and Drug Administration on Tuesday expanded its list of allowed sunscreen ingredients to include the chemical compound bemotrizinol.
Disc Medicine Aligns With FDA On Path Forward For Bitopertin In EPP
(RTTNews) - Disc Medicine, Inc. (IRON) announced it has completed a Type A meeting with the U.S. FDA regarding the CRL for its NDA of bitopertin in erythropoietic protoporphyria (EPP). The company con...
Alterity Therapeutics (ATHE) Gets FDA Nod for Phase 3 Program
Alterity Therapeutics (ATHE) Gets FDA Nod for Phase 3 Program
Alterity Therapeutics (ATHE) Secures FDA Agreement for Phase 3 ATH434 Trial
Alterity Therapeutics (ATHE) Secures FDA Agreement for Phase 3 ATH434 Trial
Joe Lonsdale on SpaceX: A critical company in the middle of the biggest industrial revolution ever
Joe Lonsdale, 8VC founding partner and Palantir co-founder, joins 'Squawk Box' to discuss the upcoming SpaceX IPO, Nasdaq rule changes, state of the AI IPO race, FDA overhaul, and more.
Watch CNBC's full interview with 8VC founding partner and Palantir co-founder Joe Lonsdale
Joe Lonsdale, 8VC founding partner and Palantir co-founder, joins 'Squawk Box' to discuss the upcoming SpaceX IPO, Nasdaq rule changes, state of the AI IPO race, FDA overhaul, and more.
RedHill: FDA Grants Rare Pediatric Disease Designation To Opaganib
(RTTNews) - RedHill Biopharma Ltd. (RDHL) announced the FDA has granted rare pediatric disease designation to opaganib for treatment of neuroblastoma. The rare pediatric disease designation to opagani...
Patanjali Foods receives notice from Maharashtra FDA over karela jamun juice claims
Patanjali Foods Limited has received a notice from the Joint Commissioner (Drugs), Food & Drug Administration, Maharashtra State, Nagpur Division, concerning promotional claims related to its Patanjal...
Top Biotech Gainers: TNGX Hits New High, ALVO Moves Closer To FDA Approval, ZVRA, IDYA Turn Heads
(RTTNews) - Today's top gainers include Tango Therapeutics, following encouraging pancreatic cancer trial data; Aspire Biopharma, ahead of upcoming milestones; Alvotech, after FDA acceptance of its in...
Medtronic Receives FDA Clearance for Nellcor Pulse Oximetry System With Nell-EQ Intelligent Processor, a New Technology Designed To Improve Reliability Across Diverse Patients and Conditions
This regulatory milestone follows news from earlier this year, when the company announced positive verification study results for its Nellcor pulse oximetry system with Nell-EQ intelligent processo...
Pfizer: FDA Expands HYMPAVZI Approval To Pediatric And Inhibitor Hemophilia Patients
(RTTNews) - Pfizer Inc. (PFE) announced that the U.S. FDA has approved HYMPAVZI for additional patient groups: individuals aged 12 and older with hemophilia A or B who develop inhibitors, and children...
Pfizer Says FDA Approves Expanded HYMPAVZI Indication For Hemophilia A And B
(RTTNews) - Pfizer, Inc. (PFE) announced Monday that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HYMPAVZI (marstacimab-hncq) to include the treatment of patient...
Alvotech (ALVO) Secures FDA Review for New Biosimilar AVT16
Alvotech (ALVO) Secures FDA Review for New Biosimilar AVT16